支持建设“心肌病诊疗协作网”！阿斯利康以创新合作绘就慢病防控新图景

Core Viewpoint - The China International Import Expo (CIIE) provides a significant platform for multinational companies to deepen their engagement in the Chinese market and share development opportunities [1] Group 1: Company Initiatives - AstraZeneca hosted over 30 events at the CIIE and announced multiple significant investments and collaborations [1] - During the "Chronic Disease Health Day" event, AstraZeneca focused on various health issues including hypertension, diabetes, severe asthma, and chronic obstructive pulmonary disease [1] - AstraZeneca established a strategic partnership with the Suzhou Industrial Park Oriental Huaxia Cardiovascular Health Research Institute to support the construction of a "China Cardiomyopathy Diagnosis and Treatment Collaborative Network" aimed at improving screening and treatment rates for cardiomyopathy patients [1] Group 2: Health Strategy - The "Healthy China 2030" plan emphasizes the importance of early diagnosis, treatment, and rehabilitation to achieve the goal of "national health" [1] - AstraZeneca is collaborating with various partners to build a comprehensive management system for diseases, enhancing the standardization of diagnosis and treatment to ensure quality medical services reach a broader population [1]